UPDATE: FDA panel OKs Bard’s Lutonix balloon

June 13, 2014 By Ingrid Mezo Leave a Comment

UPDATED June 13, 2014, with comments from panel members.

An FDA advisory panel yesterday recommended approval for the Lutonix drug-eluting balloon made by C.R. Bard (NYSE:BCR).

The FDA’s Circulatory Systems advisory panel unanimously voted in favor of the Lutonix DCB, finding it safe & effective and ruling that its benefits outweigh its risks, although they did note data for effectiveness was not robust and that further study of the device’s effects on women is needed.

"In terms of the [effectiveness] outcome, is it statistically significant? Yes. And is it clinically relevant? I’m hearing from the panel that it is moderately or modestly clinically important, but if you’re in that group that’s benefiting, I think overall the committee is saying that this is a clinically relevant endpoint that’s met statistical significance," said panel chairman Dr. Richard Page of the University of Wisconsin School of Medicine & Public Health.

The Lutonix DCB is an over-the-wire percutaneous PTA catheter with a paclitaxel-based drug coating on the surface of the balloon. It is compatible with a 0.035" guidewire and has balloon sizes ranging from 4 mm to 6 mm in diameter and 40 mm to 100 mm in length and is available in 75 cm, 100 cm and 130 cm working lengths, according to FDA background materials released ahead of the meeting.

Peripheral arterial disease (PAD), or plaque build-up in non-coronary blood vessels, is estimated to be present in around 8 million people in the U.S., including 12-20% of those individuals older than age 60.3, the federal watchdog agency noted. It narrows arteries, compromises blood flow to lower extremities, causes leg pain and can lead to disability and amputation.

Current treatment options include use of PTA alone and other permanently placed drug eluting stents, but restenosis remains a general concern.

"I work in this area and there’s a great unmet need here, and I wish the efficacy and safety were a little more robust, but I voted yes, I do believe in the data," said Dr. Daniel Simon of New Jersey’s Vascular Access Center at West Orange.

Dr. Edwin Gravereaux, of Brigham and Women’s Hospital in Boston, agreed.

"It certainly proved to be as safe as balloon angioplasty, it possibly met the endpoint for mild improvement and I look forward to seeing what it can do in the future," Gravereaux said.

Lutonix was developed as device-drug combination that is not a permanent implant, but aims to reduce restenosis compared to PTA alone. If the FDA follows its panel’s recommendation, it would be the first non-permanent drug-device combination approved for treating new, or not previously stented, restenotic lesions in the U.S.

In terms of a post-approval study, the panel was unanimous that more patients need to be collected for a minimum of 2 years; some panelists said they’d like to see a longer follow-up period.

"Specifically, we want to know more about longer-term in U.S. women, and we would really like to ideally understand the issue of the relationship to smoking. Some sort of relevant clinical endpoint would be nice, at least covered over the first couple of years," Page explained.

Several panelists noted that Lutonix could also be useful for indications beyond those studied so far.

"I urge the sponsor to increase the robustness of the database by increasing the numbers in the registry and also to go onto areas like acute ischemia, et cetera, because I do think this is promising," noted Dr. John Somberg of Rush University Medical Center in North Carolina.

BREAKING: Medtronic wins FDA approval for Micra AV
Medtronic (NYSE:MDT) has won FDA approval for its Micra AV — greatly expanding the number of people who could potentially benefit from leadless pacemaker technology. The medical device giant plans to start offering the Micra AV in a limited number of implanting centers in the coming weeks, with a full launch expected in the spring. FDA… […]
FDA reclassifies some medical image analyzers
The FDA today imposed stricter regulations on certain radiological medical image analyzers, reclassifying them from Class III to Class II. Affected products include computer-assisted detection (CADe) devices for breast cancer mammography, breast-lesion ultrasound, and lung-nodule and dental-caries radiography, the agency said. It defines these devices as those intended to identify, mark, highlight, or in any… […]
Medline Industries temporarily halts EtO sterilization at Illinois plant
This article has been updated with a comment from Medela. Medline Industries has temporarily closed its Waukegan, Ill., medical device sterilization operation to install nearly $10 million in emissions upgrades. The privately owned company uses the carcinogenic gas ethylene oxide (EtO) to sterilize its own and other companies’ devices at the plant. Medline did not… […]
Mojo Vision developing ‘smart’ contact lens
Mojo Vision is working with the FDA to develop a smart contact lens to help people with low vision. The lens overlays real-time contrast and lighting enhancements with zoom functionality and recently won FDA breakthrough device designation. “Receiving the Breakthrough Device Designation is a significant step in our research and development process. We look forward to… […]
FDA to EPA: Leave us out of your ethylene oxide rule
This article has been updated with comments from the FDA. The FDA has asked the Environmental Protection Agency to leave the FDA out of its proposal for stricter regulation of ethylene oxide (EtO) emissions, and the EPA complied. In an interagency comment on the EPA’s proposed rule governing commercial EtO users — which includes medical… […]
Clippart debuts stepper-controlled flow valve
Clippard recently launched a new stepper-controlled proportional valve for precision flow control. The Eclipse valve uses the industry’s most robust and powerful miniature linear actuator, according to Cincinnati-based Clippard. The patent-pending Eclipse is designed for liquid and gas delivery, medical, analytical and industrial automation requiring ultra-fine resolution and repeatability. The design also allows for custom… […]
Supporting regulatory affairs departments to address clinical requirements under new MDR
By Dietmar Falke and Jaap Laufer, Emergo Group The May 25, 2020 MDR deadline is approaching rapidly, and by now many medical device manufacturers are aware that the MDR requires the proactive collection of post-marketing clinical follow-up (PMCF) data. Get the full story here at the Emergo Group’s blog. The opinions expressed in this blog… […]
5 tips to raise funding for your medical device
Securing funding can be a long and tedious process, and medical device businesses must work to position themselves as especially attractive to potential investors to maximize success and accelerate the fundraising process. Jon Speer, Greenlight Guru According to Alejandro Cremades, author of The Art of Startup Fundraising, it can take from six to nine months… […]
FDA recognizes latest ISO 14971 as medical device consensus standard
By Mark Leimbeck and Stewart Eisenhart, Emergo Group The US Food and Drug Administration has granted Recognized Consensus Standard status to the third edition of the ISO 14071 risk management standard for medical devices and IVD products. Get the full story here at the Emergo Group’s blog. The opinions expressed in this blog post are… […]
Synaptive Medical updates Modus V surgical microscope
Synaptive Medical announced that its U.S. and Canadian Modus V robotic digital microscope now includes updates such as additional 3D visualization and voice-activated control. The Modus V is a robotically controlled digital microscope used as part of Synaptive’s BrightMatter surgical suite designed for less invasive, patient-specific approaches in complex cranial procedures. The Modus V provides similar… […]
New machine can preserve donor livers for 1 week
Researchers in Switzerland have built a perfusion machine that can preserve human livers for transplantation for a week or more, potentially slashing the number of donor livers that must be discarded due to time-related deterioration. Existing perfusion technology can preserve a donor liver for up to 24 hours. The team of surgeons, biologists and engineers… […]